In cases of ESR1 mutation-positive metastatic disease, the matched primary tumors when tested have been predominantly mutation negative, suggesting that many of these mutations are selected for under therapeutic pressure and during tumor progression (5,14). Here, ESR1 is linked to neoplasm.